The product of a collaboration between NeoGenomics and ConcertAI; CTO-H is a software-as-a-service solution in hematological malignancies for research analytics, clinical trial design, and clinical trial operational optimization. As the industry’s most advanced clinical hematology solution, CTO-H is pushing the boundaries of population scale real-world data and generative AI Solutions for clinical development in hematology , with its unprecedented scale, longitudinality, and biomarker depth. CTO-H is available as a pre-release solution for evaluation as of this announcement and general availability on Jan. 17, 2025.